Beyond current successes, Eli Lilly is innovating with a potential game-changing oral GLP-1, orforglipron. Read why I ...

After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...

Eli Lilly & Co.’s experimental weight-loss pill helped patients shed pounds without serious side effects in a clinical trial, ...

Eli Lilly & Company (NYSE:LLY) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential.

India's drug regulator on Thursday approved the launch of pre-filled injector pens of Eli Lilly's blockbuster weight-loss drug, Mounjaro, giving the company more options to compete with rival Novo ...

Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the company aims to announce in the third quarter trial results for the ...

A GLP-1 in pill form from Eli Lilly shows promising results for weight loss and Type 2 diabetes treatment in a trial. FDA approval is expected in 2026.

Lilly reckons that the new plants will employ around 3,000 workers, including engineers, scientists, operations personnel, and lab technicians when up and running, with another 10,000 working on ...